Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical Minocycline Foam FXFM244
Minocycline Foam FXFM244 · 1 trial · 1 indication
Comparison between the efficacy of topical minocycline foam and the control emollient. This will be completed by a dermatologist or dermatology resident that will be blinded to which side was treated with which intervention. Assessment will be completed through a visual analog used by the assessor where REDCap will assign a numeric value based on the position of the marking. The blinded photo reviewer will be informed whether the photo is a baseline or follow-up photo, but will be blinded to which side of the body was treatment or control. The photos will be marked to indicate the side of the body, and the photo reviewer will be asked to compare the left baseline side to the left follow-up side, and similarly the right baseline to the right follow-up, using a visual sliding analogue scale, where REDCap will assign a numeric value based on the position of the marking indicator. Average response to treatment among all patients will be determined.
| Arm | Type | Description |
|---|---|---|
| Experimental Half of the Body | EXPERIMENTAL | Participants will apply the investigational topical medication to one half of the body that they choose |
| Control Half of the Body | PLACEBO_COMPARATOR | Participants apply the control topical emollient without active ingredient to the contralateral half of the body |
| Name | Type | Description |
|---|---|---|
| Topical Minocycline Foam FXFM244 | DRUG | Topical minocycline foam that will be applied to half of the subject's body that will be chosen by the subject. |
| Control | OTHER | Control topical emollient that will be applied to the contralateral half of the body. |
Inclusion Criteria: * Age ≥ 9 years * Clinical diagnosis of CARP Exclusion Criteria: * Current or recent (within 6 months) use of oral minocycline * Pregnancy or breastfeeding * History of intracranial hypertension, autoimmune disorder, liver/kidney disease * Immunocompromised status * Hypersensi...
Minocycline Foam FXFM244 is an investigational topical foam being developed for the treatment of Confluent and Reticulated Papillomatosis (CARP), a dermatologic condition. It is a small molecule formulation of minocycline intended for topical application. The drug is currently in early clinical development and has not been approved by regulatory authorities.
Minocycline Foam FXFM244 targets the 30S ribosomal subunit of bacteria. By binding to this subunit, the active ingredient minocycline inhibits bacterial protein synthesis. This mechanism is relevant to its proposed use in Confluent and Reticulated Papillomatosis (CARP), a skin condition that may involve microbial factors.
Minocycline Foam FXFM244 is being developed by Journey Medical Corporation, a biopharmaceutical company. Journey Medical Corporation is publicly traded under the ticker symbol DERM. The company is advancing this topical minocycline foam through clinical development for the treatment of Confluent and Reticulated Papillomatosis (CARP).
Minocycline Foam FXFM244 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in an early-phase clinical trial to evaluate its safety and efficacy in patients with Confluent and Reticulated Papillomatosis (CARP).
Minocycline Foam FXFM244 is being evaluated in one clinical trial registered as NCT07462702, titled 'Topical Minocycline for CARP'. This is an early Phase 1, placebo-controlled study that is not yet recruiting. The trial plans to enroll 35 participants aged 9 years and older with Confluent and Reticulated Papillomatosis (CARP).
Yes, Minocycline Foam FXFM244 is also known as Topical Minocycline Foam FXFM244. Both names refer to the same investigational drug product being developed by Journey Medical Corporation for the treatment of Confluent and Reticulated Papillomatosis (CARP). The drug is a topical foam formulation of minocycline.